Ordering Recommendation

Preferred test for FFPE tissue at time of diagnosis. Use to detect prognostically important genomic abnormalities in leukemias/lymphomas and solid tumors involving loss/gain of DNA or loss of heterozygosity (LOH). May be used to monitor disease progression and response to therapy.

New York DOH Approval Status

Testing is not New York state approved. Specimens from New York clients will be sent out to a New York state-approved laboratory.

Specimen Required

Patient Preparation
Collect

Tumor tissue

Specimen Preparation

Formalin fix (10 percent neutral buffered formalin) and paraffin embed tissue.
Protect from excessive heat. Transport 10 slides, each with 5-micron unstained sections or four 20-micron scrolls or tissue block. Tissue block will be returned after testing. Transport tissue in a tissue transport kit (ARUP supply #47808) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787.

Storage/Transport Temperature

Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months.

Unacceptable Conditions

Specimens fixed or processed in alternative fixatives or heavy metal fixatives (B-4 or B-5).

Remarks

If multiple specimens (blocks or slides) are sent to ARUP, they must be accompanied by one of the following: an order comment indicating that the ARUP pathologist should choose the specimen most appropriate for testing (e.g., "Choose best block"), or individual orders for each sample submitted. A Pathologist Block Selection Fee (ARUP test code 3002076) will be added to orders that utilize the first option. If multiple specimens are sent to ARUP without a request for pathologist block/slide selection or individual orders, they will be held until clarification is provided.

Stability

Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable

Methodology

Molecular Inversion Probe Array

Performed

Sun-Sat

Reported

14-21 days

Reference Interval

Interpretive Data

For detection of copy number alterations and loss of heterozygosity in FFPE specimens.
Refer to report.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Compliance Category

Laboratory Developed Test (LDT)

Note

Samples must contain a region with at least 50 percent tumor.

Hotline History

N/A

CPT Codes

81277

Components

Component Test Code* Component Chart Name LOINC
2002148 Block ID 57723-9
2010230 Cytogenomic MIP Array, FFPE 62375-1
2010231 EER Cytogenomic MIP Microarray, FFPE 11526-1
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • aCGH
  • array CGH
  • Array Comparative Genomic Hybridization
  • CGH
  • Chromosomal Microarray
  • CMA
  • Microarray
  • oncology, formalin-fixed, paraffin-embedded, FFPE
  • Single-nucleotide-polymorphism (SNP) array
  • tissue
  • tumor
  • Whole Genome Array
Cytogenomic Molecular Inversion Probe Array FFPE Tissue - Oncology